Sims ST, Rehrer NJ, Bell ML, Cotter JD. Endogenous and exogenous female sex hormones and renal electrolyte handling: effects of an acute sodium load on plasma volume at rest. J Appl Physiol 105: 121-127, 2008. First published April 24, 2008 doi:10.1152/japplphysiol.01331.2007.-This study was conducted to investigate effects of an acute sodium load on resting plasma volume (PV) and renal mechanisms across the menstrual cycle of endurancetrained women with natural (NAT) or oral contraceptive pill (OCP) controlled cycles. Twelve women were assigned to one of two groups, according to their usage status: 1) OCP [n ϭ 6, 29 yr (SD 6), 59.4 kg (SD 3.2)], or 2) NAT [n ϭ 6, 24 yr (SD 5), 61.3 kg (SD 3.6)]. The sodium load was administered as a concentrated sodium chloride/ citrate beverage (164 mmol Na ϩ /l, 253 mosmol/kgH2O, 10 ml/kg body mass) during the last high-hormone week of the OCP cycle (OCP high) or late luteal phase of the NAT cycle (NAThigh) and during the low-hormone sugar pill week of OCP (OCP low) or early follicular phase of the NAT cycle (NAT low). The beverage (ϳ628 ml) was ingested in seven portions across 60 min. Over the next 4 h, PV expanded more in the low-hormone phase for both groups (timeaveraged change): OCP low 6.1% (SD 1.1) and NATlow 5.4% (SD 1.2) vs. OCP high 3.9% (SD 0.9) and NAThigh 3.5% (SD 0.8) (P ϭ 0.02). The arginine vasopressin increased less in the low-hormone phase [1.63 (SD 0.2) and 1.30 pg/ml (SD 0.2) vs. 1.82 (SD 0.3) and 1.57 pg/ml (SD 0.5), P ϭ 0.0001], as did plasma aldosterone concentration (ϳ64% lower, P ϭ 0.0001). Thus PV increased more and renal hormone sensitivity was decreased in the low-hormone menstrual phase following sodium/fluid ingestion, irrespective of OCP usage. oral contraceptive pill; citrate; hypervolemia; hyperhydration; estradiol; progesterone BODY WATER AND ELECTROLYTE balance are critical for normal cellular function and maintaining adequate blood and plasma volume (PV) and osmolality, yet natural and synthetic female sex hormones have various effects on water and electrolyte balance. Thus understanding the interactions of female sex hormones and their synthetic analogs and the fluid regulatory system is crucial. The two most influential female sex hormones are estrogen and progesterone, both of which change in concentration across the menstrual cycle and are governed by oral contraceptive pill (OCP) usage. These two hormones influence sodium and water distribution and thus fluid compartment volumes and dynamics. Primarily, it is known that estrogens favor fluid retention by activating the renin-angiotensin-aldosterone system and that progesterone is able to antagonize this event (21). Estrogen enhances vasodilation and capillary permeability and acts centrally to lower the operating set point of plasma osmolality (Posm) (a leftward shift in AVP sensitivity) (21, 22, 28, 30, 38) . Progesterone competes directly with the same mineralocorticoid receptor as aldosterone, which may cause a transient natriuresis (20) .
oral contraceptive pill; citrate; hypervolemia; hyperhydration; estradiol; progesterone BODY WATER AND ELECTROLYTE balance are critical for normal cellular function and maintaining adequate blood and plasma volume (PV) and osmolality, yet natural and synthetic female sex hormones have various effects on water and electrolyte balance. Thus understanding the interactions of female sex hormones and their synthetic analogs and the fluid regulatory system is crucial. The two most influential female sex hormones are estrogen and progesterone, both of which change in concentration across the menstrual cycle and are governed by oral contraceptive pill (OCP) usage. These two hormones influence sodium and water distribution and thus fluid compartment volumes and dynamics. Primarily, it is known that estrogens favor fluid retention by activating the renin-angiotensin-aldosterone system and that progesterone is able to antagonize this event (21) . Estrogen enhances vasodilation and capillary permeability and acts centrally to lower the operating set point of plasma osmolality (Posm) (a leftward shift in AVP sensitivity) (21, 22, 28, 30, 38) . Progesterone competes directly with the same mineralocorticoid receptor as aldosterone, which may cause a transient natriuresis (20) .
Although the effects of estrogen and progesterone on PV in women are relatively well known via acute infusions and manipulation of hormone concentrations, there is limited research on the effects of the chronic perturbations of menstrual cycle hormones on water and sodium handling. Moreover, these effects may not be the same with the chronic use of OCPs, where adaptations may be evident with regard to fluid regulatory functions. Combined OCP exhibit three to five times the bioactivity of endogenous estrogen; the progestin component of OCP does not compete with the mineralocorticoid receptor (8, 17, 20) . Thus unopposed effects of ethinyl estradiol on fluid regulation may induce extracellular fluid expansion at a greater volume than observed with natural endogenous estrogen (17␤-estradiol). The "placebo week" of OCP regimes is of additional interest, as it is often referred to as "low hormone" or "hormone free." This concept is erroneous, as OCP agents do not produce complete ovarian suppression. Residual ovarian activity has been observed in women taking preparations containing 50 mg ethinyl estradiol, and lower estrogen doses have been associated with even less ovarian suppression (5, 9, 27) . Coupled with the secondary effects of residual metabolites in other tissues (e.g., the kidney), fluid dynamics of this placebo week are still unknown.
The main purpose of this project was to investigate fluid balance perturbations, renal-sodium sensitivity, and responses during hormonal "extremes" of the menstrual cycle, particularly with regard to the impact of chronic OCP usage during the placebo week on sodium and water regulation. This was evaluated by inducing a sodium-mediated PV expansion using a high-sodium beverage at rest during the last highhormone week of the OCP cycle (OCP high ) or the late luteal phase of the natural cycle (NAT high ) and during the low-hormone sugar pill week of the OCP cycle (OCP low ) or during the early follicular phase of the natural cycle (NAT low ). It was hypothesized that hypervolemia would occur in both phases of the menstrual cycle, regardless of pill usage, with the greatest expansion occurring in OCP low followed by the NAT low . It was also hypothesized that the renal responses to the sodium load would be blunted in the luteal and high-hormone phases due to the resetting of baseline osmotic and AVP sensitivity.
METHODS

Participants
Thirteen healthy, eumenorrheoic, endurance-trained female cyclists [peak aerobic power (V O2peak) 52 ml⅐ kg Ϫ1 ⅐ min Ϫ1 (SD 2); 26 yr (SD 6), 60.8 kg (SD 4.8)], aged 18 -35 yr, with no history of cardiovascular or renal disease, no contraindications to OCPs, and taking no other medication, were recruited. Twelve women completed the study: six were on triphasic OCPs (OCP , Table 1 ), and six were not on any contraceptive pill (NAT). All women had regular menstrual cycles (ϳ28 days, 26 -29 days). All women on the triphasic OCP had been following the same schedule of pills for at least 12 mo before testing. Before participation, all participants were informed of the nature and demands of the investigation, after which they gave written, informed consent. The study was approved by the Human Ethics Committee of the University of Otago. All participants were familiar with the experimental protocols and conditions, and all had participated in previous laboratory trials.
Preliminary Testing
All participants initially underwent an incremental cycling test to exhaustion to ensure that they met the criteria for being categorized as "well trained" [train Ն 5 times/wk and have V O2peak Ͼ 50 ml O2 ⅐ kg body mass (BM) Ϫ1 ⅐ min Ϫ1 ]. The V O2peak test was conducted on a separate day, in temperate conditions (19 Ϯ 2°C), 1-2 wk before experimental testing. The test comprised incremental increases in work rate to exhaustion, on an electromagnetically braked bicycle ergometer (Velotron, Racermate, Seattle, WA) during which O 2 consumption, CO2 production, and heart rate were measured.
Experimental Testing
Each participant performed two identical sodium-loading trials: one in NATlow or OCPlow and one in NAThigh or OCPhigh. Sodium loading was via ingestion of a concentrated sodium beverage (3), as described below. Experimental trials were on days 4 -6 and 21-22 for an endogenous 28-day cycle, and on days 18 -20 (end of the third week of active pills high-hormone phase) and days 24 -26 (days 3-5 of placebo week) for a triphasic OCP cycle. Participants were asked to self-monitor menstrual cycle by recording the brand name and cycle of the pill or, in nonpill users, by recording basal temperature. The slight variation between participants in day of testing was due to normal fluctuations in individual cycle length (24) . The order of testing was counterbalanced.
Standardization
Verification of phase of the menstrual cycle was conducted by assessing plasma estrogen ([E 2]P) and progesterone concentrations from the baseline blood sample, and oral temperature logs (NAT) or by day of pill (OCP), before the sodium loading protocol was undertaken. To standardize for training effects on PV, participants maintained a training diary of duration, mode, and intensity of activity, and replicated this for consistency throughout the 2 wk preceding each trial. Furthermore, each participant completed a 60-min controlled exercise bout in the laboratory at 50% V O2peak 24 h before each testing day, with no further exercise until the in-laboratory testing. Participants refrained from consuming soy-based products (due to phytoestrogen effects) and nonsteroidal anti-inflammatory drugs [due to effects on glomerular filtration rate (GFR)] throughout the study period. The same meal (low-moderate sodium; no alcohol, soy, or caffeine permitted) was consumed on the evening before each testing session, and the participant drank 750 ml of water throughout that evening. An additional 500 ml of water were consumed between breakfast and the start of the testing protocol. Participants also consumed a standardized breakfast (13 g protein, 10 g fat, 63 g carbohydrate, 1,680 kJ, 265 mg Na ϩ ), which was provided and was consumed between 2.5 and 2 h before experimentation. Urinary specific gravity (USG) was measured in an initial baseline sample, at least the second void of the day, to verify similar hydration status in all tests (USG Յ 1.020).
Study Protocol
On arrival at 0900, each participant voided her bladder and had BM measured (Ϯ10 g, Wedderburn Scales, Auckland, New Zealand). The participant was then seated for 10 min before catheter placement (22-gauge Teflon intravenous catheter) in the antecubital or other suitable forearm vein of the left arm. To ensure a steady-state PV and constituents, the participant remained seated for an additional 15 min before any blood sample was taken.
Sodium Loading
On withdrawal of the baseline samples without stasis, the participant began 1 h of high-sodium beverage ingestion of 10 ml/kg BM, given in seven equal portions, one every 10 min. The beverage comprised 164 mmol Na ϩ /l [AstroAde, as developed by Greenleaf et al. (10 -12) and was used previously in hypervolemia studies (10 -12, 25, 26) ].
Upon complete ingestion of the beverage, the participant remained seated, during which time blood and urine sampling was done. Urine samples were taken 10 min after blood sampling. Participants were required to walk for 2 min before every urine sample, after the blood sampling, to ensure posture standardized, but also minimally artifactual, effects on PV (Fig. 1 ).
Blood and Urine Analysis
All blood samples (17 ml each) were separated into aliquots for analysis of hematocrit (Hct), hemoglobin concentration ([Hb]), plasma sodium concentration ([Na ϩ ]P), Posm, plasma creatinine ([Cr]P), plasma arginine vasopressin ([AVP]P), and aldosterone ([ALD]P). A 2-ml aliquot was analyzed immediately for [Hb] (Hemoximeter, OSM3 Radiometer, Copenhagen, Denmark) and Hct, in quadruplicate. Blood for Hct was drawn into capillary tubes and centrifuged for 6 min at 3,000 rpm (Hawklsey Microcentrifuge, Sussex, UK) and read using a modified microcapillary tube reader (Damon/IEC division, Needham Heights, MA); the measurement error was Ϯ0.25%. One of the remaining three additional aliquots of blood (5 ml each) was transferred into a tube containing heparin for Posm determination. The last two aliquots were transferred into tubes containing EDTA for determination of [AVP] P, [ALD]P, creatinine, [E2]P, and progesterone and progestins ([P4]P). All three tubes were then centrifuged for 10 min at 6°C and 3,000 rpm (model GS-15R Centrifuge, Beckman-Coulter, Fullerton, CA).
USG was measured in triplicate with a hand refractometer (ATAGO, Tokyo, Japan). Plasma and urine samples were put on ice during the protocol and then stored at Ϫ80°C until analyses for osmolalities and electrolyte and hormone concentrations, conducted after completion of the study. Posm was measured using vapor point depression (Osmometer, model Vapro5520, Wescor, Logan, UT). Urine and plasma electrolyte and hormone concentrations were measured at the local health board medical laboratory (Otago Southern Community Laboratories) using indirect ion-specific electrode technique (Aeroset/c8000 Indirect Ion Specific Electrodes analyzer, Abbott, Chicago, IL). Creatinine clearance was determined through log-linear equation of [Cr] P/creatinine concentrations in urine ([Cr]U) (Jaffe reaction, Abbott reagents). The [AVP]P was measured using an "in house" antiserum, with synthetic AVP (Ferring or Sigma) used for standards and preparation of 125 I-labeled AVP using chloramine T and purification by HPLC. Samples were extracted with acetonitrile (1:2 acetonitrile-plasma), and the supernatant was dried before assay. A 3-day preincubation step at 4°C is followed by a further 3 days at 4°C after the addition of the 125 I-labeled AVP. Separation of bound and free hormone is by polyethylene glycol plus-globulin precipitation. The [ALD] P was measured using the solid-phase antibody RIA method (Biosource Europe). The [E2]P was measured via a Sorin (sensitive) RIA kit (Sorin Biomedica Diagnostics, Saluggia, Italy). The [P 4]P was measured using the commercial conjugate-antibody method (ELISA kit, Assay Designs, Ann Arbor, MI), with sample concentrations determined against a standard curve. Intra-and interassay coefficients of variation, respectively, for the midrange standards were for [AVP] P (23.2 pg/ml) 5.10 and 9.80%; [ALD]P (147 pg/ml) 5.48 and 6.52%; [E2]P (115 pg/ml) 2.80 and 6.00%, and [P4]P (1.5 ng/ml) 3.61 and 4.80%.
Calculations
Changes in PV from baseline were estimated from changes in Hct and [Hb] using the following equation (6):
where subscripts t and 0 denote measurements at time t and at baseline, respectively. Hb is in g/100 ml, and Hct is a fraction. Hct was multiplied by 0.96 and then 0.91 to correct for trapped plasma and the venous-to-whole blood Hct excess, respectively. GFR (ml ⅐ min Ϫ1 ⅐ m Ϫ2 ) was estimated from creatinine clearance (ClCr) by the following equation:
Where [Cr]U and [Cr]P are in mg/dl; UVol is urine collection volume in ml, and t is urine collection time in minutes and is normalized to body surface area of each individual from height and mass (7) .
Urine Na ϩ excretion was calculated as the product of urine sodium concentration ([Na ϩ ]U) and UVol (ml 
Statistical Analysis
Mixed models were used to model each of the outcomes as a function of time and hormonal state. The repeated-measures nature of the study design was taken into account by using the covariance structures available in the SAS (version 9.1) procedure MIXED. Measurements were assumed to be more highly correlated within than between participants and also within than between treatments within a subject.
Each outcome was modeled with a mixed model that included the order (first or second trial), the hormonal state (2 levels), time (5 levels), and the interaction of hormonal state with time. A significant (P Ͻ 0.05) interaction would indicate a difference in the profiles across time of the outcome between the two hormone states. Covariates of female sex hormones (progesterone, estrogen, OCP, or NAT), renal hormones, and the interaction of the main effects were included in the model. If the interaction term was not significant, a model, which included treatment and the main effects of time and hormone state, was computed. Differences in least squares means for each of the outcomes and 95% confidence interval (CI) were calculated from the model and were considered statistically significant at P Ͻ 0.05. Means are given with SD in parentheses.
Sample size calculation. The desired statistical test is two-sided at an ␣-level of 0.05, with 80% power to detect a difference. On the basis of pilot work, 80% power was determined sufficient to detect a significant alteration in PV expansion, [AVP] P, [ALD]P, Posm, and [Na ϩ ]. For a two-sided test, the calculated sample size is six participants per group.
RESULTS
Participant Compliance
To ensure participant compliance, training, diet, temperature logs (NAT), and pill usage (OCP) were collected and reviewed the morning of the second experimental session. All participants were deemed euhydrated based on USG (Յ1.015). All participants completed all documentation and standardization procedures requested. Participant baseline characteristics are reported in Table 2 .
Acute PV Changes
There were significant phase, but not group, differences with regard to the effect of sodium loading on PV expansion. Across the 4-h postloading time, there was greater PV expansion in OCP low and NAT low vs. OCP high and NAT high [change (⌬) 6.14 (SD 1.12) and 5.41% (SD 1.16) vs. ⌬3.88 (SD 0.85) and 3.45% (SD 0.83), P ϭ 0.0178; 95% CI: ⌬3.39, ⌬4.34; Fig. 2 ]. OCP usage did not alter the hypervolemic response (P ϭ 0.27), and this was not dependent on phase of cycle (P ϭ 0.32).
Renal Responses and Na ϩ Regulating Hormones
Across the experimental session, there was an increase of AVP with the sodium loading in the high-hormone phase of both OCP high and NAT high [AVP: 1.82 (SD 0.3) and 1.57 pg/ml (SD 0.5)] compared with OCP low and NAT low [1.63 (SD 0.2) and 1.30 pg/ml (SD 0.2); 95% CI: 0.27, 0.12 pg/ml; Figs. 3 and 4 ]. There were significant differences in Posm between phases [OCP high Across the experimental session, an attenuation of aldosterone concentration was observed between phases (P Ͻ 0.05), with a difference between high-and low-hormone status of 110.8 pg/ml (95% CI: 163.3, 52.5 pg/ml; P ϭ 0.00). This attenuation occurred, regardless of pill usage (difference: OCP high vs. OCP low 101.9 pg/ml, P ϭ 0.00; NAT high vs. NAT low 99.6 pg/ml, P ϭ 0.00). There was no evidence of a difference in the slopes of aldosterone between low-(151 pg/ml) and high-hormone (245 pg/ml) status, independent of pill usage (P ϭ 0.08; 95% CI of the difference: 151, 245 pg/ml, Table 3 ). There were, however, significant differences in urine sodium excretion across the 5-h experimental sessions, with more [Na ϩ ] U excreted in the high-hormone phase, regardless of group (P ϭ 0.05, 95% CI of the difference: 10.98, 8.44 mmol/l), in contrast to the low-hormone phase.
Renal Water and Sodium Handling
Means (SD) are presented in Table 4 . There were significant differences in urinary output across the 5-h experimental sessions, with a greater urinary output in NAT across phases [NAT high and OCP high : 1,068 (SD 90) vs. 928 ml (SD 88), P ϭ 0.03; 95% CI: 119, 298 ml; NAT low and OCP low: 1,133 (SD 108) vs. 938 ml (SD 20), P ϭ 0.03; 95% CI: 180, 279 ml]. No significant differences were found between groups in GFR (P Ͼ 0.05, Table 4 ), although significant increased FE Na ϩ (P ϭ Values are means (SD). NAThigh and NATlow, late luteal and early follicular phase of the natural cycle, respectively. V O2peak, peak aerobic power; ͓E2͔P, ͓P4͔P, ͓AVP͔P, ͓ALD͔P, ͓Na ϩ ͔P: plasma concentration of estrogen, progestin, arginine vasopressin, aldosterone, and sodium, respectively; Posm, plama osmolality; Uosm, urinary osmolality; MCHC, mean cell hemoglobin concentration; MCV, mean cell volume. *Day 1 of OCP is the first day of active pills; day 1 of natural 28-day cycle is the first day of menses. †P Ͻ 0.05 between phases; ‡P Ͻ 0.05 between groups. Fig. 2 . Changes in plasma volume (%). Values are means (SD) for 12 women with natural (NAT; n ϭ 6) and oral contraceptive pill (OCP)-mediated (triphasic; n ϭ 6) menstrual cycles across the 5-h experimental period for both high-(OCPhigh, NAThigh) and low-hormone (OCPlow, NATlow) conditions. *P Ͻ 0.05. Fig. 3 . Relationship between the change in plasma arginine vasopressin concentration ([AVP]P) and plasma osmolality (Posm) across the 5-h experimental period of the low-hormone conditions. Data are means (SD) for 12 women with NAT (n ϭ 6) and OCP-mediated (n ϭ 6) menstrual cycles. 0.04) with significantly lower FE H 2 O (P ϭ 0.05) in OCP high and NAT high were observed compared with the NAT low hormone phases, but not OCP low . A significantly increased FE Na ϩ was observed between NAT low and OCP low (P ϭ 0.05), with no difference in FE H 2 O between the two groups.
DISCUSSION
This investigation is the first to document that an acute sodium-fluid load expands PV at rest in both high-hormone and low-hormone phases of an endogenous or exogenous driven menstrual cycle of endurance-trained women. The PV expansion observed in women is similar to that observed previously (25) and to that observed in men (26) . The changes in PV are also similar to those conducted with less trained and, therefore, also presumably less hypervolemic individuals (3, 10 -12) . However, most of the resting hypervolemic studies have not included women, or, if they have, the women have been tested in the follicular phase of the natural menstrual cycle, or during the first week of "active" hormone pills of an OCP-driven cycle. Thus, in the present investigation, the efficacy of sodium loading was examined in women across the endogenous and exogenous menstrual cycle, including the phases in which estrogen elevations are associated with a fluid redistribution from the vascular to the extravascular space. An attenuation of hypervolemia in the high-hormone phase compared with the low-hormone phase was observed, which indicated that stimulation of the renin-angiotensin-aldosterone system and an alteration of AVP sensitivity and/or action in the kidney occurred.
PV Expansion
It is well known that estrogens cause PV expansion, most likely via their actions on the capillary endothelium to increase the transcapillary escape of proteins and thus water (22, 36) . These changes in oncotic pressure will induce changes in body fluid distribution within the extracellular fluid, independent of sodium concentration. In the present study, a high-sodium beverage did induce a transient hypervolemia in trained women cyclists, and there was a difference of the %PV change between phases of the menstrual cycle. The greatest expansion was found in the sugar pill phase of OCP (OCP low ). However, this expansion was transient, and no differences were observed between OCP low and the high-hormone groups at 300 min. To note, although the PV expansion of the NAT low was slightly less than that of the OCP low , this expansion was not transient. At 300 min, the PV expansion of NAT low was ϳ3% greater than that of the other three groups.
This discrepancy in expansion between the low-hormone groups may indicate residual metabolite activity of levonorgestrol and ethinylestradiol in the renal tissue. To review, OCP agents do not induce complete ovarian suppression during the placebo week (5, 16, 27) . Moreover, plasma 17␤-estradiol concentrations of OCP low were similar to those of NAT low in the baseline data of both groups; thus we would have expected a similar response in fluid retention (duration and %expansion) between OCP low and NAT low . With the observed drop in PV expansion of OCP low at 180 min (not NAT low ), it may indicate residual levonorgestrol may have antagonized the estradiol effects on fluid retention and renal sodium retention activity of aldosterone.
AVP and Free Water Clearance
The results of the present study illustrate a greater AVP response to the sodium loading in the high-hormone phase of both groups, concomitant with a lower Posm and higher [E 2 ] P . In humans, it has been established that basal Posm is higher in the follicular than in the luteal phase, with the threshold for AVP release lowest in the luteal phase (29, (31) (32) . Moreover, estrogens upregulate the number of AVP binding sites (28, 32, 38) , which increase the pressor response in the renal vascular bed. These observations are further supported by the result of the present study. We observed a lower Posm and elevated [AVP] P in the high-hormone state, regardless of pill or no pill usage, from resting throughout the experiment period. A slight increase in [AVP] P was also observed in response to the sodium load. The free water clearance between groups was similar; however, FE H 2 O was different between phases, with a lower FE H 2 O observed in the high-hormone phase of both groups (concomitant with a higher urine osmolality and an attenuated urine flow volume). This difference may be due to a resetting of osmoregulatory mechanisms (i.e., downward resetting of Posm and elevated resting [AVP] P ) and the subsequent effects on the translocation of aquaporin-2 (AQP-2). AVP exerts its antidiuretic effect in the collecting ducts of the kidney by activating the water channel AQP-2. Our baseline data illustrated a phase difference of resting [AVP] P (elevated in the high-hormone phase of both groups), which may have influenced an increase in AQP-2 expression, which was further indicated by the reduced FE H 2 O in the high-hormone groups.
GFR and FE Na ϩ
Nitric oxide (NO) is an important regulator of glomerular hemodynamics in the kidney. Specifically, NO synthase activity is important to the overall function of the tubuloglomerular feedback system, as a modulator of sodium transport, as well as blood flow and GFR. NO within the kidney is known to contribute to low renal vascular resistance and stimulate diuresis and natriuresis, independent of renal perfusion pressure (4) . Additionally, inhibition of renal NO synthase has been shown to reduce the pressure-natriuresis curve, which may increase natriuresis in all tubular segments (4, 18) . This is consistent with the increased FE Na ϩ and [Na ϩ ] U of our participants in the sugar pill week and high-hormone phase, regardless of whether it was an endogenous or an OCP-mediated cycle. The increased FE Na ϩ may be due to a few pressure-mediated interactions. Pechere-Bertschi et al. (23) reported there was no blood pressure increase with a sodium ϩ water volume load in OC users, as a salt-induced renal vasodilation was observed (an increase in GFR coupled with an increase in filtration fraction, but no change in renal blood flow). As we observed a drop in GFR across all conditions, we may conclude that a decrease in renal perfusion pressure occurred concomitant with an increased filtration fraction. It is well known that estrogen increases endothelium-dependent vasodilation via NO, but estrogen also induces an increase in NO in the renal tissues, in particular the vasa recta capillaries. This precapillary vasodilation will increase medullary hydrostatic pressure, which, with NO, will reduce sodium reabsorption (increase in FE Na ϩ) and increase fluid reabsorption (as observed by the decreased renal free water clearance).
General Conclusions and Recommendations
The purpose of this study was to examine how the OCP and NAT menstrual cycle affect sodium and volume regulatory mechanisms and to examine efficacy of a highly concentrated sodium (164 mmol/l) beverage as a means to induce acute hypervolemia across the endogenous and exogenous menstrual cycle. PV expansion across both types and phases of the menstrual cycle occurred; however, the differences between the high-and low-hormonal states indicate that alterations to renal responses to a sodium load occur across the menstrual cycle. The present data indicate that adaptation to OCPs may result in a new baseline set point for body fluid regulation, although this study was not designed to allow distinction to be drawn on the relative effects of the different estrogens and progesterones. Further research is needed to investigate the complex interactions and any adaptations that may occur with chronic OCP use; in particular, any adaptations that may either contribute to or protect women from fluid balance conditions like hypertension and deep vein thrombosis over the long term.
